Schonfeld Strategic Advisors
PDLI

Schonfeld Strategic Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Schonfeld Strategic Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-18,656
Closed -$59K – 1368
2019
Q2 		$59K Buy
+18,656
New +$60.5K ﹤0.01% 940
2018
Q1 		– Sell
-13,069
Closed -$36K – 1084
2017
Q4 		$36K Buy
+13,069
New +$40.1K ﹤0.01% 720

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Brandes Investment Partners
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Schonfeld Strategic Advisors's PDLI Position: Q3 2019 in Review

Schonfeld Strategic Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q3 2019, closing a stake of 18,656 shares — an estimated $59K sold.

Schonfeld Strategic Advisors first reported a position in PDLI in Q4 2017 and held it in 2 quarters. The position peaked at $59K in Q2 2019. 140 funds tracked by Wall St. Rank hold PDLI as of Q3 2019.

  • Schonfeld Strategic Advisors reported no remaining PDL BioPharma, Inc. position as of Q3 2019 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 18,656 PDL BioPharma, Inc. shares in Q3 2019, an estimated $59K.
  • Schonfeld Strategic Advisors first reported a position in PDL BioPharma, Inc. in Q4 2017 and held it in 2 quarters.
  • Schonfeld Strategic Advisors's PDL BioPharma, Inc. position peaked at $59K in Q2 2019.
  • 140 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2019.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.